White blood cell treatment aids wound healing

07/10/2013 | Wall Street Daily

A concentrated mixture of white blood cells has demonstrated an ability to heal persistent wounds of patients suffering from diabetes or restricted blood flow. The treatment, called CureXcell, has a 70% success rate in closing the wounds of 5,000 patients to date, according to its developer, the Israeli company MacroCure. CureXcell is undergoing a Phase III trial in the United States, and the company hopes to have FDA approval by 2017.

View Full Article in:

Wall Street Daily

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Santa Clara, CA
Director, Site Quality Management
Minneapolis, MN